Navigation Links
Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine
Date:10/12/2009

SAN MARINO, Calif., Oct. 12 /PRNewswire/ -- Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world's first and, so far only, tumor-targeted genetic medicine to be validated in the clinic. Administered as stand-alone therapy in late-stage cases of chemotherapy-resistant cancer, Rexin-G has once again accomplished what standard cancer treatments and even much-touted biologics have failed to do: that is, to bring forth the benefits of remission in otherwise intractable metastatic cancers. Three recent cases of Stage IV metastatic cancer, namely (i) osteosarcoma, (ii) prostate cancer, and (iii) pancreas cancer, demonstrated that Rexin-G treatments alone led to clinical remission of disease in each of these poor prognosis patients. Even more remarkable, perhaps, are the profiles of the latter two patients, which signal the advent of Rexin-G as the vanguard of a new class of exceedingly precise, selective, and effective anti-cancer agents, and which typify a newfound societal acceptance and acknowledgement of the real-world promise and potential of this uniquely-targeted genetic medicine.

Remarkably, a Catholic priest, who was previously bedridden and in withering pain, suffering from end-stage prostate cancer that had spread to his bones, received successive courses of Rexin-G, during which time the bone pain was relieved, the PSA tumor markers fell, the bone tumors stopped growing, and even the previously inoperable primary tumor disappeared on follow-up CT scans. As the priest's bones began to heal and strengthen, he arose from his bed and is currently saying daily Mass and delivering lectures in the seminary. What is even more remarkable is that this revered man of the cloth was over ninety years old at the time of his treatment and remission. This past week, the latest good news comes from the trenches of Stage IVb pancreas cancer, where a complete clinical remission was documented in a patient undergoing Rexin-G treatment as stand-alone therapy in an ongoing U.S. Phase I/II clinical trial.

According to Erlinda Maria Gordon, M.D., Medical Director of Epeius Biotech, "It is gratifying to learn that more and more eminent medical oncologists around the world are recommending Rexin-G as 'Best Care' for patients with refractory metastatic disease, and even more gratifying to show how truly effective Rexin-G at these doses can be in eradicating such difficult cancers." Indeed, as the unprecedented single-agent efficacy of Rexin-G is incontrovertibly demonstrated in an increasing number of chemo-resistant cancers, the progressive steps of these intrepid pioneers may provide a rational basis of hope and expectation for many when standard therapy has failed. Rexin-G is approved for the treatment of all solid tumors in the Philippines, and has been granted both Orphan Drug Status for pancreas cancer, osteosarcoma and soft tissue sarcoma, and Fast Track Designation for pancreas cancer by the U.S. FDA.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about our pipeline of proprietary biotechnologies currently available for clinical development and/or new product development, please visit us at http://www.epeiusbiotech.com.

*(Logo Link: Send2Press.com/mediaboom/09-1012-EpeiusBio_300dpi.jpg)

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com

    Note to editors:
    Additional Epeius news/RSS:
    http://profiles.send2press.com/Epeius_Biotechnologies.shtml

SOURCE Epeius Biotechnologies Corporation


'/>"/>
SOURCE Epeius Biotechnologies Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
2. Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
3. New approach for growing bone comes from Duke preclinical research
4. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
5. Clinical Genomics Continues Collaborative Research With CSIRO
6. HerbalScience Releases Results of Pilot Clinical Study on Efficacy of Its Proprietary Elderberry Extract in Addressing Flu-Like Symptoms
7. Boston Scientific Announces Exclusive Sponsorship and First Enrollments of MADIT-RIT Clinical Trial
8. Medicago begins human clinical testing with its avian flu pandemic vaccine
9. MacuSight(R) Provides Clinical Development Update for Perceiva(TM)
10. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
11. ClearTrial Launches Industry-first Software Platform for Integrating Clinical Trial Operations from Plan to Cash™, Driving Operational Efficiencies and Accelerating Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 2016 , ... NeuMedics Inc. is pleased to announce that CEO Iain Duncan ... June 2, 2016. The session begins at 1:10 PM and Iain will present the ... used as a topical agent and a treatment for ophthalmic complications of diabetes. , ...
(Date:5/27/2016)... ... ... Doctors in Italy, Japan, the UK and the US have reached some ... and its link to malignant mesothelioma. Surviving Mesothelioma has just posted the details of ... , The studies analyzed for the new report included more than 3,447 cancer ...
(Date:5/26/2016)... 26, 2016  Agriculture nutrients are in the news ... is running their nitrate removal system on ... and coastal regions nationwide are painting the ... widespread issue. NECi Superior Enzymes, a biotechnology ... developed a new, easy to use device that fits ...
(Date:5/26/2016)... , May 26, 2016 Despite the ... value in this space. Today,s pre-market research on ActiveWallSt.com directs ... Health Inc. (NASDAQ: RDUS ), Cerus Corp. (NASDAQ: ... ARWR ), and Five Prime Therapeutics Inc. (NASDAQ: ... briefings at: http://www.activewallst.com/ On ...
Breaking Biology Technology:
(Date:3/15/2016)... -- Yissum Research Development Company of the Hebrew ... Hebrew University, announced today the formation of Neteera ... human biological indicators. Neteera Technologies has completed its first ... ... emissions from sweat ducts, enables reliable and speedy biometric ...
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... http://www.apimages.com ) - --> - Renvoi : ... - --> --> ... solutions biométriques, fournit de nouveaux lecteurs d,empreintes digitales ... LF10 de DERMALOG sera utilisé pour produire des ...
(Date:3/11/2016)... India , March 11, 2016 ... a new market research report "Image Recognition Market by ... Application (Marketing and Advertising), by Deployment Type (On-Premises and ... Forecast To 2022", published by MarketsandMarkets, the global market ... 2015 to USD 29.98 Billion by 2020, at a ...
Breaking Biology News(10 mins):